Obesity is increasingly recognized as a major modifiable determinant of atrial fibrillation (AF). Although body mass index and other clinical measures are useful indications of general adiposity, much recent interest has focused on epicardial fat, a distinct adipose tissue depot that can be readily assessed using non-invasive imaging techniques. A growing body of data from epidemiological and clinical studies has demonstrated that epicardial fat is consistently associated with the presence, severity, and recurrence of AF across a range of clinical settings. Evidence from basic science and translational studies has also suggested that arrhythmogenic mechanisms may involve adipocyte infiltration, pro-fibrotic, and pro-inflammatory paracrine effects, oxidative stress, and other pathways. Despite these advances, however, significant uncertainty exists and many questions remain unanswered. In this article, we review our present understanding of epicardial fat, including its classification and quantification, existing evidence implicating its role in AF, potential mechanisms, implications for clinicians, and future directions for research.
Introduction
Population studies have demonstrated that body mass index, a measure of overall adiposity, is a strong predictor of AF. These data have shown that every 5 kg/m 2 increase in body mass index is associated with an approximate 10-30% higher risk of AF across a range of clinical settings. 1, 2 This association is particularly important in the context of progressive increases in global AF prevalence. 3 -5 It is estimated that AF will affect almost 18 million in Europe alone by 2060. 3 The increasing impact of adiposity on these trends is driven by concurrently burgeoning obesity rates worldwide. Obesity already accounts for almost one-fifth of AF cases, and its population attributable-risk is likely to continue rising as developing countries undergo epidemiologic transition. 6, 7 Thus, these data underscore the central importance of adiposity as part of preventative and management strategies to reduce the public health burden of AF. 8, 9 As with other cardiovascular diseases, however, body mass index is a relatively crude anthropometric measure of excess adiposity and individuals with similar body mass index can have variable risk of AF.
While part of this heterogeneity is mediated by other risk factors for AF (age, gender, hypertension, heart failure, obstructive sleep apnoea, and the like), variation in body fat distribution is another potential explanation. Other clinical measures, such as waist circumference and waist-to-hip ratio, have been advocated as alternative methods of assessing body fat distribution. However, even these measures only provide an approximate indication of regional excess adiposity. With increasing advances and availability of non-invasive imaging techniques, such as computed tomography (CT) and cardiac magnetic resonance (CMR) imaging, much evidence is now available on the risk of disease associated with distinct adipose tissue depots. Particularly relevant to cardiometabolic disease is the visceral adipose tissue compartment, which has been associated with greater risk compared with the more superficial subcutaneous adipose tissue compartment. 10 This review will explore our present understanding of AF and epicardial fat, an anatomically relevant component of the overall visceral adipose tissue compartment. Issues discussed include its classification and quantification, existing research supporting an association with AF, current implications for clinicians, and future directions for study.
Epicardial fat and related adipose tissue depots: anatomy and definition
Given a lack of standard taxonomy and varied use of definitions, a brief review of anatomy and terminology is first warranted. We summarize epicardial fat and other related adipose tissue definitions based on their use in current literature in Table 1 .
Epicardial fat is most commonly defined as adipose tissue surrounding the heart, located between the myocardium and the visceral pericardium (Figure 1 ). This should be distinguished from paracardial fat (adipose tissue located external to the parietal pericardium) and pericardial fat (often defined as paracardial fat plus all adipose tissue located internal to the parietal pericardium). 11 However, it should be noted that the term pericardial fat is sometimes used to alternatively describe adipose tissue within the pericardial sac (equivalent to the above definition of epicardial fat) 12 or adipose tissue located external to the parietal pericardium (the above definition of paracardial fat). 13 Other terms that have been used variably to refer to these adipose tissue depots include cardiac ectopic fat, intra-pericardial fat, extra-pericardial fat, mediastinal fat, and intra-thoracic fat. 11, 12, 14, 15 Although epicardial fat can be considered as part of total-body visceral adipose tissue, most studies assessing associations of visceral adipose tissue with cardiovascular conditions do not include epicardial (or any intra-thoracic) fat with their imaging technique, and instead quantify either intra-abdominal fat alone or a combination of intra-abdominal and intra-pelvic fat. 16 Given the heterogeneous use of terminology, and also because the metabolic characteristics of each visceral adipose tissue compartment may differ, it is prudent to carefully review the definition of epicardial fat and other visceral adipose tissues used by authors in any individual study.
At a molecular level, fat exists as lipid in the form of triglycerides. 16 While body fat is mostly found in adipose tissue (i.e. that specialized loose connective tissue laden with adipocytes that can be quantified volumetrically with CT and CMR imaging modalities) it also exists within other tissues. Ventricular intramyocardial fat, for example, can been assessed using magnetic resonance spectroscopy. 17 However, intramyocardial fat should be considered distinct from the epicardial fat depot. Furthermore, non-invasive assessment of intramyocardial fat within the thin atrial walls is beyond the limits of current imaging technology, which has thus far limited its study with regards to AF pathophysiology.
Physiology and pathophysiology of epicardial fat: implications for arrhythmogenesis
Embryologically, epicardial fat originates from the splanchnopleuric mesoderm (associated with the gut), which also gives rise to mesenteric and omental fat. 11 There are no fascial boundaries between epicardial fat and the myocardium. In contrast, paracardial fat is separated from the myocardium by the pericardium and is derived from the primitive thoracic mesenchyme. 13 While epicardial fat is perfused by the coronary arteries, paracardial fat is supplied by branches of the internal mammary artery. 13 Possible physiological functions of epicardial fat include lipid storage for myocardial energy, thermoregulation, protection of autonomic ganglia and nervous tissue, and regulation of coronary artery vasomotion and luminal size. A range of pathophysiologic mechanisms could contribute to an association between epicardial fat and AF ( Figure 2) . Epicardial fat may lead to AF via structural and electrical remodelling of the atria by both direct (e.g. by the infiltration of adipose tissue leading to altered atrial electrophysiological properties) and indirect mechanisms (e.g. by acting as a source for paracrine modulators of myocardial inflammation and oxidative stress). Alternatively, it may be possible that epicardial fat influences triggers from the pulmonary veins and other sites that interact with a remodelled atrial substrate to sustain AF. These are described in more detail below and are divided into probable and possible mechanisms according to available evidence.
Probable mechanisms
Fatty infiltration Previous studies have noted that an abundance of epicardial fat is associated with direct adipocyte infiltration into the underlying atrial myocardium. 18, 19 In an ovine model, for example, sustained obesity led to the accumulation of epicardial fat with pronounced myocardial infiltration by adipocytes, particularly over the posterior left atrial wall. 19 In contrast, non-obese control animals had less epicardial fat accumulation and minimal adipocyte infiltration into the myocardium. Such direct fatty infiltration separating myocytes could directly result in conduction slowing or anisotropy akin to that seen with microfibrosis. 20, 21 Indeed, epicardial fat was independently associated with atrial conduction time in a large population study as indicated by P-wave indices. 22 Direct fatty infiltration (and other potential mechanisms) may be further fuelled by the imhomogeneous contact between patchy peri-atrial epicardial fat and the atrial myocardium, promoting conduction heterogeneity. 23 
Fibrosis
It is increasingly appreciated that epicardial fat is a metabolically active tissue and a rich source of adipokines. 11 Moreover, direct anatomic contiguity, adipocyte infiltration, and accumulation of adipokines secreted from epicardial fat within the pericardial sac may facilitate paracrine effects on the atrial myocardium that promotes fibrosis. Supporting this theory is data demonstrating that secretome from human epicardial fat, but not from subcutaneous adipose tissue, has marked pro-fibrotic effects on rat atrial myocardium. 24 Furthermore, the adipokine activin A, a member of the TGF-b superfamily secreted by epicardial fat, is able to reproduce such atrial fibrosis, an effect that can be blocked by anti-activin A antibodies. 24 It may be possible that other pro-fibrotic adipokines known to be secreted by epicardial fat may also contribute to remodelling of the atrial myocardium. For example, matrix metalloproteinases 2 and 7, key regulators of extra-cellular matrix activity, are known to contribute to atrial fibrosis and are upregulated during AF. 25 Furthermore, overexpression of TGF-b1
can also cause selective atrial fibrosis and AF. 26 
Inflammation
There are a number of lines of evidence that point to a role for local inflammatory processes in the pathophysiology of AF. Firstly, markers of inflammation, such as C-reactive protein, IL-6, IL-8, IL-1b, and TNF-a, have been associated with the incidence, severity, and recurrence of AF. 27 -30 These markers are secreted by epicardial fat, and may have local pro-inflammatory effects on the adjacent atrial myocardium that facilitate arrhythmogenesis. Secondly, another study noted that epicardial fat had greater 18-fluorodeoxyglucose uptake on positron emission tomography when compared with subcutaneous or other visceral adipose tissue depots; these observations may be consistent with an inflammatory activity of epicardial fat that contributes to the development of AF. 31 Finally, systemic anti-inflammatory therapies such as corticosteroids appear to reduce atrial remodelling and AF incidence.
32,33
Possible mechanisms
Oxidative stress Epicardial fat is known to be a source of reactive oxygen species. 34 Previous data have shown that the production of reactive oxygen species is greater in human epicardial fat than it is in subcutaneous adipose tissue. 34 In animal models, inhibition of reactive oxygen species with antioxidants appears to attenuate atrial remodelling induced by rapid pacing. 35 Taken together, these results suggest that oxidative stress from epicardial fat may play a role in the genesis of AF.
Cardiac muscle activity
In analyses on peri-atrial, peri-ventricular, and peri-coronary epicardial fat samples from human patients, only peri-atrial epicardial fat was observed to express genes involved in oxidative phosphorylation, cell adhesion, cardiac muscle contraction, and calcium signalling pathways. 36 These transcriptomic characteristics suggest that peri-atrial epicardial fat may have unique effects on cardiac muscle activity distinct from other epicardial fat sub-depots that may be related to the development of AF.
Adipocyte-related gene expression
In an experimental study that utilized human and pig atrial samples, both AF and rapid pacing were associated with significant changes in atrial gene expression consistent with the induction of an adipocyte-related expression profile. 37 These intriguing findings, pointing to a role for AF and rapid pacing in promoting adipocyte differentiation and atrial adipogenesis, suggests that obesityrelated AF may facilitate self-persistence in a positive-feedback fashion.
Autonomic dysfunction
The autonomic nervous system is thought to play a crucial role in the initiation and maintenance of AF, and ganglionated plexi are located in epicardial fat. 38, 39 Activation of these ganglionated plexi can cause both parasympathetic and sympathetic stimulation, resulting in shortening of action potential duration and increases in calcium transient, respectively, in the atrial myocardium. 40 Indeed, intrinsic cardiac nerve activity has been noted to invariably precede the onset of AF in experimental models. 41 As a result, multiple clinical studies have investigated the role that neuromodulation may have in controlling AF, particularly by ablation of ganglionated plexi of the intrinsic cardiac nervous system. 38 It may be possible that encasing epicardial fat influences these ganglionated plexi and thus contributes to arrhythmogenesis. This is supported by more recent evidence suggesting that botulinum toxin injection into epicardial fat pads may reduce cardiac autonomic nervous activity and AF by potentially suppressing ganglionated plexi. 42 
Diastolic dysfunction
Epicardial fat has been associated with measures of left ventricular structure and diastolic dysfunction in previous studies. 43 -45 Such effects might be mediated by mechanisms discussed above, or alternatively, by mechanical compression. This could lead to atrial dilatation which has also been shown to occur in individuals with voluminous epicardial fat. 45 Triggers While it seems likely that epicardial fat may contribute to a remodelled atrial substrate via the above mechanisms, another possibility is an effect on AF triggers. Triggers are localized sources of spontaneous, rapid, and repetitive electrical activity, particularly from the pulmonary vein, that can initiate and maintain AF. 46 Increases in overall adiposity have previously been shown to be associated with shortened effective refractory periods in the pulmonary veins, leading to speculation that adiposity can predispose to AF initiation. 47 Indeed, there is some evidence to that areas of epicardial fat accumulation correlate with sites of high dominant frequency, suggesting that epicardial fat may influence AF triggers. 48, 49 Such an effect of epicardial fat on the electrophysiological characteristics of pulmonary vein and atrial myocytes to facilitate triggers could potentially be mediated by any of the mechanisms discussed above.
Non-invasive imaging assessment of epicardial fat
Epicardial fat can be quantified non-invasively using CT, CMR, and echocardiography (Figures 3-5) . One consequence of the increasing availability and use of non-invasive imaging is that epicardial fat can be simultaneously assessed in scans taken for multiple indications. There are various advantages and disadvantages to each modality which we discuss below and summarize in Table 2 . Furthermore, we discuss the potential clinical implications of the various fat quantification methods used.
Computed tomography
The majority of clinical studies to date examining associations of epicardial fat depots with cardiovascular disease have utilized CT. With high spatial resolution, epicardial fat can be readily and reproducibly identified with CT ( Figure 3 ). Attenuation value ranges can be defined to allow for either manual or semi-automatic quantification of adipose tissue (typically 2195 to 245 HU). 12, 50 An advantage of CT (and CMR) techniques is that volumetric quantification of epicardial fat is possible, though investigators in previous studies have also used CT to assess single-slice epicardial fat area and epicardial fat thickness. 51 -53 One important disadvantage of CT is that exposure to ionizing radiation may limit use, particularly if serial (followup) assessments are desired.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance offers excellent spatial resolution and is considered the 'gold standard' for imaging adipose tissue ( Figure 4) . Moreover, it is also the only imaging modality we are aware of in which volumetric quantification of epicardial fat has been validated ex vivo. 23, 54 In addition to peri-ventricular adipose tissue, we have validated the use of a semi-automated method to accurately and reproducibly quantify the patchy and smaller peri-atrial pericardial fat from standard CMR sequences, which may be more pathogenically relevant to the adjacent atrial myocardium. 23 Furthermore, CMR is able to concurrently assess atrial and ventricular volumes, myocardial (mainly ventricular) replacement with diffuse fibrosis, and myocardial perfusion, all of which may provide additional insights into AF pathogenesis. While CMR is not limited by ionizing radiation hazards associated with CT scanning, it is more costly and often less available than other modalities.
Echocardiography
Echocardiography is the most accessible and affordable imaging modality to assess epicardial fat ( Figure 5) . However, it is not without key limitations. Two-dimensional echocardiography has only been used to measure epicardial fat thickness in previous studies. 55, 56 In addition, an assumption is made using echocardiography that the pericardial window separation contains only epicardial fat, which may not necessarily be the case. Although volumetric assessment of epicardial fat is theoretically possible with three-dimensional echocardiography, it is likely to be poorly sensitive for identifying fat and, to the best of our knowledge, has not been used or validated.
Epicardial vs. pericardial fat
Most studies focusing on AF have assessed either epicardial or pericardial fat. Ideally, the more relevant epicardial fat depot would be separately quantified. Epicardial fat is anatomically contiguous to the myocardium, which is likely to facilitate pathophysiological interaction via mechanisms outlined earlier in this review. Furthermore, they have distinct embryological and vascular characteristics as discussed above, and clinical evidence outlined below support differential effects of these distinct adipose tissue depots. However, the ability to only measure epicardial fat requires an accurate identification of the pericardium. Even when using CMR, which is considered the 'gold standard' imaging modality, spatial resolution may not be sufficient to consistently and accurately define the pericardium. 23 Thus, the decision by clinicians and researchers to measure either epicardial or pericardial fat may be dependent on image quality. While validation with ex vivo mass or another established technique is ideal, clinicians and researchers should first verify the intra-and inter-observer reproducibility of their institution's method at a minimum. If pericardial fat quantification is undertaken, given the difficulty in defining the pericardium, it should be appreciated that this may lead to type 2 errors in small studies, or underestimation of the true strength of associations due to the inclusion of less biologically relevant paracardial fat as discussed later, and that these need to be considered when interpreting results.
Epicardial fat volume, area or thickness
The most accurate imaging technique to assess epicardial fat burden is volumetric quantification. However, advantages of area and thickness techniques as a substitute for volume are expediency of image acquisition, lesser requirement for image analysis, and cost considerations compared with volumetric quantification. As discussed above, epicardial fat thickness can also be measured with echocardiography, which may be more available, economical, and avoids ionizing radiation from CT. These techniques may thus facilitate ready assessment of epicardial fat burden, particularly when assessing disease associations in large population studies. However, there are a number of limitations to their use. Area and thickness techniques assume that these two-and one-dimensional measurements are sufficiently sensitive to capture overall variation in epicardial fat volume. It has been shown that this may not always be the case, with epicardial fat thickness not correlating well with ex vivo fat mass. 54 Furthermore, these techniques are susceptible to greater interand intra-observer variability both at the time of imaging acquisition and analysis stage. 57 As a result, analyses using such techniques may be more susceptible to biases in small studies and render betweenstudy comparisons more difficult.
Total, peri-atrial, or peri-ventricular epicardial fat
There is a relative abundance and regularity of peri-ventricular epicardial fat compared with peri-atrial epicardial fat. 23 This fact makes imaging and analysis of peri-ventricular epicardial fat easier, and there is also a greater likelihood for otherwise-acquired scans to already contain ventricular slices. As a result, the majority of AF studies have only quantified peri-ventricular epicardial fat. 58 It is tempting to speculate however that peri-atrial epicardial fat may be more pathogenically relevant to AF initiation and/or maintenance, particularly given its local proximity to atrial muscle. Indeed, data from a recent study suggested that peri-atrial epicardial fat may be an atypical adipose tissue with distinct characteristics compared with peri-ventricular or peri-coronary epicardial fat. 36 In human epicardial fat samples, gene-profiling analyses demonstrated unique transcriptomic characteristics of epicardial fat sub-depots; while all three sub-depots shared inflammatory, extra-cellular matrix remodelling, and thrombosis pathways, only peri-atrial epicardial fat expressed genes implicated in oxidative phosphorylation, muscular contraction, and calcium signaling. 36 These results support the theory that peri-atrial epicardial fat may be more pathogenic. On the other hand, it still may be possible that assessing total or peri-ventricular epicardial fat as a surrogate for peri-atrial epicardial fat burden may be sufficient. This could be true if both sub-depots increase concurrently, if arrhythmogenesis is mediated by shared pathways, or if pathogenic mechanisms are not reliant on anatomic contiguity. Consistent with this possibility is a recent meta-analysis that could not discern any difference in the strength of associations between peri-atrial or peri-ventricular epicardial fat and AF, though such interaction tests have low statistical power. 58 More studies are required to provide further insight into the relative pathogenicity of these different sub-depots of epicardial fat.
Epicardial fat and atrial fibrillation: supporting clinical evidence Early studies
It was first suspected in the 1960s and 1970s that atrial arrhythmias may be associated with excess adipose tissue within and surrounding the heart. 59 -62 Necropsy studies demonstrated that prominent amounts of fatty deposits could be observed in some individuals, both in the interatrial septum and in the epicardial space. 59 -62 It was hypothesized at the time that 'lipomatous hypertrophy' of the interatrial septum might interrupt electrical pathways to facilitate atrial arrhythmogenesis. 63 The theory that adipose tissue may be arrhythmogenic has now gained renewed interest with the availability of modern, non-invasive imaging techniques facilitating the study of larger numbers of individuals.
Epicardial fat and atrial fibrillation
Numerous studies support an association of epicardial fat with the presence of AF. 58 In a CT analysis of 3217 individuals from the Fra- paracardial or intra-abdominal fat, was independently associated with prevalent AF. 12 Similarly, in another CT series of 300 individuals by Al Chekakie and colleagues, total epicardial fat volume was also associated with prevalent AF. 64 Other studies have sought to explore whether epicardial fat specifically surrounding the atria is related to AF. Batal and colleagues assessed 169 consecutive individuals with CT and found that peri-atrial epicardial fat thickness at the mid-left atrium was greater in patients with AF. 51 In contrast,
we have previously used cardiac CMR to quantify peri-atrial, periventricular, and total pericardial fat volumes in 130 individuals. 65 We found that pericardial fat volumes, but not measures of overall adiposity such as body mass index or body surface area, were independently predictive of prevalent AF. A recent systematic review and meta-analysis of such studies we conducted was able to characterize and compare the strength of associations between epicardial fat, measures of overall adiposity, and AF. 58 In these analyses, every 1 SD increase in epicardial fat volume was associated with 2. 
Epicardial fat vs. pericardial fat
Supporting the need for standardized terminology and quantification of adipose tissue depots is evidence suggesting that differing strength of associations may exist depending on whether epicardial or pericardial fat is measured. In the aforementioned meta-analysis, for example, overall associations appeared to be significantly greater in studies measuring epicardial fat as opposed to pericardial fat. 58 Similarly, one study that quantified both depots demonstrated an association between epicardial fat, but not paracardial fat, and AF. 12 These results may be consistent with a more biologically plausible effect of the anatomically contiguous epicardial fat, with the inclusion of less relevant other adipose tissue attenuating associations in those studies quantifying pericardial fat.
Epicardial fat and atrial fibrillation severity
A biological gradient may also exist between greater epicardial fat and AF severity, further supporting the possible arrhythmogenicity of this adipose tissue depot. Findings from previous research demonstrate that there appears to be a dose -response relationship of increasing epicardial fat along the continuum of no AF, paroxysmal AF, persistent AF, and long-lasting persistent (permanent) AF. 65 -67 Importantly, this relationship may also explain why some studies have failed to demonstrate significant associations between epicardial fat and the presence of paroxysmal AF compared to sinus rhythm. 68, 69 With greater statistical power than smaller individual studies, meta-analyses have confirmed a relationship between epicardial fat and paroxysmal AF, although the effect estimate for this relationship is smaller than the association between epicardial fat and persistent AF, consistent with a biological gradient. 58 Epicardial fat and atrial fibrillation in specific clinical settings
The possibility of an association between epicardial fat and AF has also been extended to specific clinical settings. An increasing number of individuals undergoing ablation procedures for AF, which often requiring pre-procedural imaging, has allowed for the relationship between epicardial fat and recurrent AF to be assessed. Indeed, a number of investigators have reported that increasing epicardial fat is also associated with post-ablation AF. 56, 65, 67, 69 Similarly, there may also exist a relationship between increasing epicardial fat and incident AF following cardiac surgery and recurrent AF after electrical cardioversion. 70 -72 However, not all data are consistent;
one experimental study anticipated that dissection of the anterior epicardial fat pad and a consequent reduction in parasympathetic innervation might reduce postoperative AF, and a paradoxically opposite effect was noted. 73 Clearly, further research is required.
Potential clinical implications Risk stratification
As discussed above, epicardial fat appears to be independently associated with the incidence, severity, and recurrence of AF, even after adjusting for other cardiovascular risk factors and clinical measures of adiposity. Given this, epicardial fat may therefore not only have a potential role in risk stratification to better predict incident AF but also to identify those individuals more susceptible to progressive and recurrent AF. Future research would be required to demonstrate that epicardial fat quantification could meaningfully improve risk stratification beyond readily available clinical information. In particular, standards for imaging quantification and threshold values for greater risk would need to be developed. However, the feasibility and cost-effectiveness of such an approach might not be implausible given the numerous indications for cardiac imaging that increasingly exist and the increasing contribution of adiposity to AF risk. 74 Weight loss and risk factor management Consistent with our growing understanding of the relationship between adiposity and AF is recent clinical data demonstrating the importance of weight reduction as a management strategy. 75 -77 Compelling observational and randomized evidence suggest that aggressive management of measured weight and other risk factors results in marked improvements in AF burden and symptom severity. 75 -77 Furthermore, these benefits occurred in conjunction with significant reductions in epicardial fat volumes. 78 While these studies did not specifically target individuals with increased epicardial fat, such patients may be candidates for more intensive management, particularly if other risk factors and clinical measures of adiposity (such as waist circumference and body mass index) appear to be otherwise well controlled.
Novel therapies
As discussed above, new evidence is accumulating for the role that specific pathways mediated by epicardial fat may have in atrial arrhythmogenesis. While great insights have been made, further advances are anticipated in the coming years. Although compelling evidence for pathogenic mechanisms does not invariably translate into clinically effective therapies, it may be possible that future targeting of these pathways, for example adipokines, may lead to the identification of novel therapies for the prevention and treatment of AF.
Unanswered questions and future directions
While our understanding of the relationship between epicardial fat and AF has rapidly increased in recent years, this exciting new field of research is still in its infancy. Although current clinical and epidemiological studies appear to demonstrate consistent associations between epicardial fat and AF, more research is now required to clarify whether these associations are causal. For example, it may be that associations of epicardial fat with AF are confounded by other adipose tissue depots or comorbidities such as hypertension, diabetes, and obstructive sleep apnoea. Additional evidence from larger, prospective cohort studies would supplement existing data, particularly if they are able to compare and contrast different visceral adipose tissues and sub-depots of epicardial fat. While emerging basic science and translational studies are uncovering promising pathways, our understanding will be enhanced by further investigation into these mechanisms. In this regard, genetic studies could also help unravel mechanisms and the question of causality via Mendelian randomization studies. Finally, more work is required to characterize how epicardial fat quantification may contribute to the management of at-risk or affected patients.
Conclusion
Obesity will remain a central challenge to the growing burden of AF in the coming years. While recent studies of body fat distribution have highlighted the role that epicardial fat may have in the pathophysiology of AF, additional research is ongoing. Future studies will provide greater insight into mechanisms underpinning the relationship between epicardial fat and AF, characterize how epicardial fat quantification might be used in clinical practice, and further the development of potentially novel therapies.
